−256.55USD
−32.34 MUSD
788.80 K
About NexImmune, Inc.
Sector
CEO
Kristi Jones
Headquarters
Gaithersburg
Website
Employees (FY)
6
Founded
2011
ISIN
US65344D2080
FIGI
BBG007SK6360
NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke on June 7, 2011 and is headquartered in Gaithersburg, MD.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of NEXI is 3.48 USD — it has increased by 5.45% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NexImmune, Inc. stocks are traded under the ticker NEXI.
NexImmune, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
NEXI stock is 14.38% volatile and has beta coefficient of −0.22. Check out the list of the most volatile stocks — is NexImmune, Inc. there?
One year price forecast for NexImmune, Inc. has a max estimate of 7.00 USD and a min estimate of 7.00 USD.
NEXI earnings for the last quarter are −9.25 USD per share, whereas the estimation was −11.63 USD resulting in a 20.43% surprise. The estimated earnings for the next quarter are −7.25 USD per share. See more details about NexImmune, Inc. earnings.
Yes, you can track NexImmune, Inc. financials in yearly and quarterly reports right on TradingView.
NEXI stock has fallen by 13.00% compared to the previous week, the month change is a 37.52% fall, over the last year NexImmune, Inc. has showed a 63.37% decrease.
NEXI net income for the last quarter is −5.36 M USD, while the quarter before that showed −9.85 M USD of net income which accounts for 45.62% change. Track more NexImmune, Inc. financial stats to get the full picture.
Today NexImmune, Inc. has the market capitalization of 3.90 M, it has decreased by 19.78% over the last week.
No, NEXI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NEXI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NexImmune, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 6.00 employees. See our rating of the largest employees — is NexImmune, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NexImmune, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NexImmune, Inc. stock shows the strong sell signal. See more of NexImmune, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NexImmune, Inc. future price: according to them, NEXI price has a max estimate of 7.00 USD and a min estimate of 7.00 USD. Read a more detailed NexImmune, Inc. forecast: see what analysts think of NexImmune, Inc. and suggest that you do with its stocks.